Gyroscope Therapeutics Is A Clinical Stage Gene Therapy Company Focused On Treating Ocular Diseasesparticularly Those Leading To Vision Loss And Blindnessacquired By Novartis In February 2022Gyroscope Develops One Time Gene Therapies For Conditions Like Geographic Atrophygasecondary To Age Related Macular Degenerationamd A Major Cause Of Irreversible Blindness In Older Adults Founded In 2016Gyroscope Merged With Orbit Biomedical In 2019 To Enhance Its Proprietary Orbita C Subretinal Delivery Systemwhich Allows For Precise Therapeutic Delivery To The Retinathe Company Utilizes Adeno Associated Virusaavtechnology To Address Genetic And Complement System Dysregulation In Retinal Diseasesits Lead Productgt005Is Currently In Phase Ii Trials And Aims To Restore Complement Factor I Levels In Genetically Defined Amd Patientsgyroscope Is Also Expanding Its Pipeline With Additional Gene Therapies For Retinal Diseases
